

**PRIOR AUTHORIZATION REQUEST FORM**

**VYEPTI™**

**For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

Product being requested:  Vyepti™ (eptinezumab)

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section.**

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of episodic or chronic migraines?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Has the member has a 3-month trial and failure, contraindication, or intolerance to a beta-blocker, Botulinum toxin type A, and at least 1 of the following: <ul style="list-style-type: none"> <li>• A calcium channel blocker</li> <li>• An antidepressant</li> <li>• An anticonvulsant</li> <li>• An angiotensin-converting enzyme (ACE) inhibitor</li> </ul> <b>Note:</b> if the member cannot try a beta-blocker, then 2 migraine prevention medication classes listed above must be tried.	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member tried and failed, or is contraindicated to, preferred agents Ajovy®, Emgality®, and Aimovig®?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**REAUTHORIZATION**

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does clinical documentation show a positive response to therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.**

Additional information:
Physician Signature:

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-M032  
Origination Date: 09/18/2020  
Reviewed/Revised Date: 05/18/2022  
Next Review Date: 05/18/2023  
Current Effective Date: 06/01/2022

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.